wayground logo

Free Printable Worksheets

Font size

S
M
L
XL
Worksheets

Chemo Induced Cardiotoxicity and Cancer Associated VTE

Total questions: 18

Worksheet time: 12mins

Name
Class
Date
1.

What drug chemotherapy class casues Type 1 Cardiotoxicity

a)

Anthracyclines

b)

HER-2 Agents

c)

Alkylating agents

d)

Antimetabolites

2.

Doxycycline a Type I Cardiotoxic drug has what characteristics below?

a)

Direct reversible damage

b)

Results in cellular apoptosis

c)

Incidence independent of dosing

d)

Least favorable

e)

9-18% incidence rate

3.

Type 2 Cardiotoxicity chemo medications consists of what drug class?

a)

Anthracyclines

b)

HER-2 Agents

c)

Taxanes

d)

Antimetabolites

4.

HER-2 agents cause ____ damage

a)

Irreversible

b)

Reversable

5.

Agents other than Anthracyclines and HER-2 agents that cause cardiotoxicity include

a)

Alkylating agents

b)

Angiogenesis inhibitors

c)

Tyrosine kinase inhibitors

d)

Immune checkpoint inhibitors

e)

Arsenic trioxide

6.

Cardiomyopathy, Myocarditis, Pericarditis, Acute coronary syndrome, Congestive heart failure, Left ventricular dysfunction are all types of

a)

Systemic Injury

b)

Hepatic Injury

c)

Cardiac Injury

d)

Neuropathic Injury

7.

Which of the following is not a patient realted risk factor for cardiac injury?

a)

Increasing age over 55

b)

Diabetes

c)

Right Ventricular Heart Failure

d)

Genestic Predispositions

8.

Therapy related risk facotrs for cardiac injusry include

a)

Concomitant use of mediastinal radiation

b)

Bolus administered chemotherapy

c)

Previous utilization of other cardiotoxic chemotherapies

d)

Chemotherapy (any type)

e)

Combination chemotherapy

9.

Symptoms of cardiac injury include

a)

SOB

b)

Weight loss

c)

Dizziness

d)

Stomach distention

e)

Chronic cough

10.

What diagnostic imaging test would be best for for cardiac injury diagnosis?

a)

Cardiac Magnetic Resonance Imaging (CMR)

b)

Multiple-gated acquisition (MUGA)

c)

Echocardiography (ECG)

d)

Positron Emission Tomography (PET)

11.

What is the LVEF threshold for starting cardiotoxic chemotherapy?

a)

30%

b)

45%

c)

55%

d)

75%

12.

What range of LVEF decline determines if cardiotoxicity is being caused by anthracyclines?

a)

> 30% decrease when baseline LVEF is not normal

b)

> 20% decrease in left ventricular ejection fraction (LVEF) when baseline is normal (55% or higher)

c)

> 10% decrease when baseline LVEF is not normal

d)

> 10% decrease in left ventricular ejection fraction (LVEF) when baseline is normal (55% or higher)

13.

What range of LVEF decline is seen in patients recieving HER-2 chemotherapy that determines if cardiotoxicity is occuring?

a)

10% to 55% decrease in LVEF with (s/sx) of HF

b)

5% to 55% decrease in LVEF with (s/sx) of HF

c)

10% to 55% decrease in LVEF without s/sx of HF

d)

5% to 55% decrease in LVEF without s/sx of HF

14.

Before starting a a patient on a cardiotoxic chemotherapy regimine what should be done first to help prevent cardiac injury?

a)

Evaluate/reduce cardiovascular risk prior to treatment selection

b)

Evaluate/reduce myopathy risk prior to treatment selection

c)

Evaluate/reduce stress levels prior to treatment selection

d)

Evaluate/reduce medication cost prior to treatment selection

15.

When administering anthracyclines, what measures can be taken to reduce cardiotoxicity?

a)

Be aware of cumulative lifetime dosing

b)

Only give bolus doses

c)

Administer cardio protectants (dexrazoxane)

d)

Use liposomal formulations

16.

What is the maximum lifetime dosage for doxorubicin?

a)

550 mg/m2

b)

450 mg/m2 in patients who have received mediastinal radiation

c)

1550 mg/m2

d)

1450 mg/m2 in patients who have received mediastinal radiation

17.

What medication is used in the prevention of cardiotoxicity in anthracycline use?

a)

Dexrazoxane (Zinecard®)

b)

Dexamethasone (Decadron®)

c)

Dexrazoxane (Totect®)

18.

Other than Zinecard® what medications can be used in the prevention/treatment of cardiotoxicity in patients recieving chemotherapy?

a)

ACEIs

b)

ARBs

c)

Statins

d)

Beta Blockers